Investment Opportunity

Seed Round Open

$1.5M to take a fully-validated computational platform into wet-lab, reach functional prototype, and land first customer.

Seed

Round

$1.5M

Amount

$6M

Pre-money

$7.5M

Post-money

18 months

Runway

Prototype + first sale

Goal

Why Now

One wet-lab milestone from a functional prototype

All computational phases are complete — metabolic modeling, KO screening, structural validation, scaffold design. The seed round funds the transition to physical reality.

"We are one wet-lab milestone away from a functional prototype — exactly what this seed round funds."
✓ Genome-scale metabolic model (iJDZ836)
✓ 10,440 KO pairs screened — chassis validated in silico
✓ LOV2-Jα-HEX1 + SPA1-ePDZ — pLDDT 91 & 88
✓ H-tree scaffold designed (10×10 mm, 16 ports)
✓ Provisional patent draft — 5 families, 30-day file
→ Wet-lab validation (M2–M12)

12-Month Milestones

M2

Construct six-gene chassis

PCR-verified KOs

M4

SEC-MALS on CompA_v3

R_h ≥ 28 nm

M6

BLI/SPR binding confirmed

K_d ≤ 1 µM lit

M8

Valve functional

≥50% pore closure

M10

Chip colonization

Fluorescent flow

M12

First customer

LOI from 3 labs

Use of Funds

$1.5M seed — 18 months to prototype + first sale

Category Amount %
Wet-lab startup

Tissue culture hood, incubators, −80°C, SEC-MALS service contract

 $400k 27%
Strain construction

2 RA salaries · 18 months

 $300k 20%
Founder salary + ops

18 months runway

 $250k 17%
Protein validation

E. coli / Pichia expression, purification, BLI/SPR

 $200k 13%
Chip prototyping

SU-8 masters, PDMS, photomasks, microscope time

 $150k 10%
IP legal

Provisional + non-provisional + FTO · US + PCT option

 $100k 7%
Contingency (15%)

Unforeseen costs

 $100k 7%
Total $1,500k 100%

Allocation

Wet-lab startup $400k
Strain construction $300k
Founder salary + ops $250k
Protein validation $200k
Chip prototyping $150k
IP legal $100k
Contingency (15%) $100k

Next Round

Series A · $5M · 2027

Scale production · Hire sales · Enter pharma pilots

Risk & Mitigation

Key Risks & Mitigations

Mitigation

Fallback: full-length HEX1 or engineered self-assembly domain. HEX1 oligomerization is well-characterized; compact domain variant is a conservative optimization, not a prerequisite.

Mitigation

Fallback: SpyCatcher/SpyTag system — covalent, C-terminus independent. Multiple alternative PDZ pairs identified in FTO review.

Mitigation

No published metabolic role for Δwc-1 in carbon metabolism. Contingency: alternative promoters or partial WC-1 truncations that preserve optogenetic response without growth penalty.

Mitigation

Start with RUO products only — academic and pharma R&D, no clearance required. Sivoro Start and Sivoro Organ require no FDA oversight. Dx timeline begins 2029+ with a full 510(k) runway.

Investor Materials

Ready to Learn More?

Download the full pitch deck, or reach out directly to schedule a conversation.

Download Pitch Deck (PDF) investors@sivoro.bio

Ann Arbor, Michigan · April 2026 · Pre-money $6M